https://sylentis.com/sylentis-grupo-pharmamar-inaugura-la-primera-planta-en-espana-de-fabricacion-de-oligonucleotidos/2022-07-05T10:19:01+02:00https://sylentis.com/sylentis-grupo-pharmamar-inicia-un-nuevo-ensayo-de-fase-iii-en-estados-unidos-para-evaluar-la-seguridad-del-tivanisiran-en-pacientes-con-ojo-seco/2022-07-05T10:29:33+02:00https://sylentis.com/sylentis-grupo-pharmamar-finaliza-el-ensayo-de-fase-i-con-syl1801-para-enfermedades-de-retina/2022-07-05T10:19:14+02:00https://sylentis.com/sylentis-grupo-pharmamar-inicia-un-ensayo-clinico-de-fase-i-con-syl1801-para-enfermedades-de-retina/2022-07-05T10:19:51+02:00https://sylentis.com/la-fda-autoriza-a-sylentis-grupo-pharmamar-el-inicio-del-ensayo-de-fase-iii-con-tivanisiran-para-el-tratamiento-de-la-enfermedad-de-ojo-seco/2022-06-27T17:45:48+02:00https://sylentis.com/sylentis-pharmamar-group-presents-new-results-of-tivanisiran-for-the-treatment-of-dry-eye-disease/2022-07-05T09:59:18+02:00https://sylentis.com/sylentis-grupo-pharmamar-presenta-en-arvo-su-nuevo-farmaco-para-enfermedades-de-la-retina/2022-07-05T09:59:14+02:00https://sylentis.com/sylentis-grupo-pharmamar-en-arvo-2019-con-resultados-de-dos-farmacos-oftalmicos-tivanisiran-y-syl1801/2022-06-27T17:54:15+02:00https://sylentis.com/sylentis-anuncia-resultados-de-su-ensayo-helix-de-fase-iii-con-tivanisiran-para-el-tratamiento-de-la-enfermedad-de-ojo-seco/2022-07-04T17:17:01+02:00https://sylentis.com/sylentis-grupo-pharmamar-anuncia-el-fin-del-reclutamiento-de-pacientes-para-su-ensayo-helix/2022-07-04T17:17:15+02:00https://sylentis.com/la-oms-selecciona-tivanisiran-como-denominacion-comun-internacional-dci-de-syl1001/2022-06-27T17:59:16+02:00https://sylentis.com/alnylam-pharmaceuticals-otorga-a-sylentis-una-opcion-de-licencia/2022-06-27T18:03:29+02:00https://sylentis.com/sylentis-empresa-pionera-en-la-tecnologia-del-rnai-obtiene-la-autorizacion-de-laboratorio-farmaceutico-fabricante-de-medicamentos-en-investigacion/2022-06-27T18:05:59+02:00https://sylentis.com/sylentis-presenta-nuevos-datos-para-el-tratamiento-de-la-conjuntivitis-alergica/2022-07-04T17:17:40+02:00https://sylentis.com/sylentis-presenta-nuevos-resultados-para-el-tratamiento-de-la-degeneracion-macular-asociada-a-la-edad/2022-07-04T17:19:01+02:00https://sylentis.com/sylentis-presenta-resultados-clinicos-de-tivanisiran-para-el-tratamiento-del-sindrome-de-ojo-seco/2022-07-04T17:21:02+02:00https://sylentis.com/sylentis-presenta-nuevos-resultados-de-sus-farmacos-oftalmicos-en-arvo-2018/2022-07-04T17:20:51+02:00https://sylentis.com/sylentis-presenta-nuevos-datos-sobre-tratamiento-topico-para-enfermedades-de-la-retina-evitando-las-inyecciones-oculares/2022-06-27T18:13:32+02:00https://sylentis.com/sylentis-inicia-un-estudio-de-fase-iii-para-el-tratamiento-del-ojo-seco/2022-06-27T18:14:45+02:00https://sylentis.com/sylentis-presenta-nuevos-datos-clinicos-y-preclinicos-de-la-molecula-syl1001-durante-arvo-2017/2022-06-27T18:15:53+02:00https://sylentis.com/sylentis-obtiene-resultados-positivos-en-fase-2-con-syl1001-para-tratar-el-dolor-ocular-sindrome-de-ojo-seco/2022-06-27T18:18:28+02:00https://sylentis.com/sylentis-presenta-los-resultados-de-su-ensayo-de-fase-ii-syltag-de-busqueda-de-dosis-de-bamosiran-syl040012-para-el-tratamiento-del-glaucoma/2022-06-27T18:20:23+02:00https://sylentis.com/sylentis-recibe-autorizacion-para-comenzar-el-ensayo-clinico-de-fase-iib-con-bamosiran-syl040012-para-el-tratamiento-dela-hipertension-ocular-asociada-a-glaucoma/2022-06-27T18:23:33+02:00https://sylentis.com/zeltia-informa-que-su-filial-sylentis-ha-alcanzado-el-objetivo-principal-del-ensayo-clinico-de-fase-iia-con-el-compuesto-syl040012/2022-06-27T18:24:48+02:00https://sylentis.com/zeltia-informa-que-su-filial-sylentis-inicia-la-fase-ii-de-ensayos-clinicos-con-su-compuesto-syl1001-para-el-tratamiento-del-dolor-ocular-asociado-al-sindrome-del-ojo-seco/2022-06-27T18:25:57+02:00https://sylentis.com/sylentis-participa-en-el-7o-congreso-de-la-sociedad-espanola-de-glaucoma-seg/2022-06-27T18:27:52+02:00https://sylentis.com/zeltia-informa-que-su-filial-sylentis-inicia-la-fase-i-de-ensayos-clinicos-con-su-nuevo-compuesto-syl1001-para-el-tratamiento-del-dolor-ocular-asociado-al-sindrome-del-ojo-seco/2022-06-27T18:33:57+02:00https://sylentis.com/los-primeros-pacientes-del-ensayo-clinico-de-fase-i-ii-con-syl040012-ya-han-iniciado-el-tratamiento/2022-06-27T18:35:51+02:00https://sylentis.com/sylentis-recibe-autorizacion-para-comenzar-un-nuevo-ensayo-clinico-de-fase-i-ii-con-syl040012-en-pacientes-para-el-tratamiento-de-la-presion-intraocular-elevada-y-glaucoma/2022-06-27T18:37:10+02:00https://sylentis.com/sylentis-esponsoriza-la-11a-reunion-anual-de-la-ots-oligonucleotide-therapeutics-society/2022-06-27T18:44:26+02:00https://sylentis.com/rna-interference-technologies-and-therapeutics/2022-07-04T17:50:08+02:00https://sylentis.com/sylentis-a-pharmamar-group-company-begins-a-new-phase-ii-trial-with-syl1801-for-patients-with-age-related-macular-degeneration/2022-11-23T11:45:42+01:00https://sylentis.com/sylentis-a-pharmamar-group-company-to-present-new-data-at-arvo-2023/2023-04-24T19:25:06+02:00https://sylentis.com/sylentis-a-pharmamar-group-company-announces-the-fydes-study-to-evaluate-the-safety-of-tivanisiran-in-patients-with-dry-eye-disease-has-met-its-primary-endpoint/2023-12-18T12:25:00+01:00https://sylentis.com/sylentis-a-pharmamar-group-company-appoints-andreas-segerros-as-chief-executive-officer/2024-05-28T10:16:43+02:00https://sylentis.com/sylentis-a-pharmamar-group-company-announces-the-positive-results-of-the-phase-iia-dose-ranging-study-for-syl1801-in-patients-with-age-related-macular-degeneration-amd/2025-05-05T13:32:04+02:00